ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1550

Real-World Outcomes of Anifrolumab in Systemic Lupus Erythematosus Patients at Toronto Lupus Program
Abstract Number: 2338

Real-World Outcomes of Combined Tofacitinib and TNF Inhibitor Therapy in Refractory Inflammatory Arthritis: A Tertiary Care Experience from India
Abstract Number: 1457

Real-world Patient Trajectories in Psoriasis and Psoriatic Arthritis: a Retrospective Study
Abstract Number: 0369

Real-World Persistence of Janus Kinase Inhibitors in Biologic-Experienced Patients with Rheumatoid Arthritis
Abstract Number: 1586

Real-World Safety and Efficacy of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched EUSTAR Study
Abstract Number: 0201

Real-World study of immunogenicity and safety of the adjuvant recombinant vaccine against varicella zoster virus in patients with immune-mediated inflammatory diseases treated with Janus Kinase Inhibitors in comparison with healthy individuals
Abstract Number: 0572

Real-World Treat-to-Target Strategy in Psoriatic Arthritis: 48-week Results from the MONITOR-PsA Cohort
Abstract Number: 1924

Real-World Treatment Patterns of Patients with Systemic Autoimmune Rheumatic Disease-associated Interstitial Lung Disease After Progression in The United States
Abstract Number: 1282

Real-world use of belimumab in childhood-onset SLE in Spain: cross-sectional analysis from a multicenter study (JULES registry)
Abstract Number: 2038

Real-World Use of Dual Targeted Therapy in Rheumatic Disease: A Single-Center Case Series
Abstract Number: 0400

Recent Antibiotic Exposure and Response to Treatment of Juvenile Idiopathic Arthritis
Abstract Number: 1021

Recent Trends in Cannabis Use Among Individuals with Rheumatic Diseases
Abstract Number: 2196

Recognition and Treatment of Idiopathic Granulomatous Mastitis: A Case Series
Abstract Number: 1667

Recurrent or Incident Pericarditis With Concurrent Autoimmune Disease: Stable Control With Rilonacept Interleukin-1 Pathway Inhibition
Abstract Number: 1430

Redefining BASDAI cut-offs: implications for patients’ eligibility for initiating biologic disease-modifying antirheumatic treatment in axial spondyloarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].